Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma.

Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma.

Acta Derm Venereol. 2011 Sep;91(5):562-7

Authors: Quéreux G, Brocard A, Peuvrel L, Nguyen JM, Knol AC, Dréno B

Abstract
The aim of this retrospective study was to assess the efficacy and tolerance of intravenous rituximab in multifocal primary cutaneous follicle centre lymphomas (PCFCL). Eleven patients with a multifocal PCFCL were treated with rituximab (MabThera®) administrated intravenously. After four infusions, an objective response was observed in 90% of patients, and one month after all the infusions (median of 6 infusions) all the patients had an objective response and complete remission was obtained in 7 of 11 patients (64%). Follow-up ranged from 9 to 65 months (median: 30 months). Local disease recurrence was observed in five patients. The median progression-free survival time after the end of treatment was 23.6 months. This study is the largest series of patients with multifocal primary PCFCL treated with intravenous rituximab. This therapy is a safe and effective treatment and could represent an excellent alternative treatment to radiotherapy.

PMID: 21629975 [PubMed – in process]

This entry was posted in Acta Derm Venereol and tagged . Bookmark the permalink.